StageZero Life Sciences

What StageZero Life Sciences does

StageZero Life Sciences is a publicly traded Canadian biotechnology company (TSX Venture NEX: SZLS.H; OTCQB: SZLSF) that develops and commercializes blood-based diagnostic tests for early cancer detection. Its core technology is the patented Sentinel Principle platform, an mRNA gene-expression analysis system that detects disease-specific molecular signatures in circulating blood cells; this platform has been validated in more than 9,000 patients and used clinically on more than 100,000 patients in North America. The commercial product portfolio includes the Aristotle multi-cancer blood test (which screens for nine cancers — ovarian, breast, endometrial, cervical, bladder, prostate, colorectal, liver, and stomach — from a single sample), ColonSentry (the company's first-to-market liquid biopsy for colorectal cancer), BreastSentry, and a Prostate Health Index test. Testing is performed at the company's CLIA-certified and CAP-accredited laboratory in Richmond, Virginia.

In 2021, StageZero executed a deliberate vertical-integration strategy, acquiring Care Oncology Clinic, Clinics Operations Limited, and the Health Clinics Business to extend beyond diagnostics into the AVRT cancer-prevention program, the COC Protocol adjunctive therapy offering, and telehealth/clinical services across North America and Europe. Revenue is generated through direct B2B sales to self-funded employer health plans (with claimed >50% healthcare-cost reductions via early detection), dedicated first-responder/firefighter programs (with the International Association of Fire Fighters named as a customer), direct-to-consumer testing ordered through a telehealth platform with mobile phlebotomy support, and acquired clinical service operations that contribute approximately $4 million in annual revenue. With 11–50 employees and operations in Richmond Hill, Ontario and Richmond, Virginia, StageZero remains a small-cap, micro-revenue company whose strategic direction hinges on scaling employer and firefighter channel adoption and realizing synergies from its 2021 acquisitions.

Name

StageZero Life Sciences

Legal name

StageZero Life Sciences Ltd.

Website

https://stagezerolifesciences.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

StageZero Life Sciences is a publicly traded biotech that develops blood-based mRNA diagnostic tests for early cancer detection (Aristotle multi-cancer panel, ColonSentry) and, following 2021 acquisitions, operates telehealth clinical services and the AVRT prevention and COC Protocol therapy programs in North America and Europe.

Ownership category

akta.pro rank

Product category

Molecular Cancer Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Blood-based cancer diagnostics
• Multi-cancer detection tests
• Liquid biopsy diagnostics
• Cancer prevention programs
• Employer health screening

Headquarters

HQ city

Richmond Hill

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: Revenue from blood-based cancer detection tests including ARISTOTLE multi-cancer panel, ColonSentry, and other diagnostic tests performed in their CAP accredited and CLIA certified laboratory in Richmond, VA.
2. Telehealth and Prevention Programs: Revenue from AVRT cancer prevention program and COC Protocol adjunctive therapy services offered through Care Oncology Clinic telehealth platform with physician oversight.
3. Employer Health Programs: B2B revenue from employer-sponsored cancer testing and prevention programs targeting self-funded health plans. Programs aim to reduce catastrophic cancer claims by 50%+ through early detection.
4. Clinic Operations Revenue: Revenue from acquired Clinics Operations Limited business providing specialist clinical services in Europe and North America, adding approximately $4 million in annual revenue.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

StageZero Life Sciences develops and commercializes blood-based diagnostic tests for early cancer detection and prevention. Its flagship Aristotle test detects molecular signatures of nine cancers from a single blood sample using the proprietary Sentinel Principle mRNA technology platform, complemented by ColonSentry, BreastSentry, and Prostate Health Index tests, the AVRT cancer prevention program, and the COC Protocol adjunctive cancer therapy offered through Care Oncology Clinic.

Product overview

StageZero Life Sciences offers a suite of advanced diagnostics for early cancer detection and prevention. The core platform is the Sentinel Principle® technology, an mRNA-based blood analysis system that generates disease-specific gene expression signatures. The flagship product is Aristotle®, a multi-cancer blood test detecting nine cancer types from a single sample. Complementary offerings include AVRT™ for cancer prevention through metabolic risk assessment, ColonSentry® (the first liquid biopsy for colorectal cancer), BreastSentry®, and Prostate Health Index. The company also operates the Care Oncology Clinic providing adjunctive cancer therapies and offers employer and firefighter-specific programs. All testing is performed through the company's CLIA-certified and CAP-accredited laboratory in Richmond, Virginia.

Differentiator

Problem solved

Functional benefit

Brands

• ARISTOTLE: Multi-cancer blood test panel that detects molecular signatures of multiple cancers (Ovarian, Breast, Endometrial, Cervical, Bladder, Prostate, Colorectal, Liver, and Stomach) from a single blood sample.
• AVRT
• ColonSentry
• BreastSentry
• Prostate Health Index
• Sentinel Principle
• Care Oncology

Products and services

• Aristotle Multi-cancer blood test that uses mRNA technology to simultaneously detect molecular signatures of nine cancers (Breast, Ovarian, Cervical, Endometrial, Liver, Colorectal, Stomach, Prostate, Bladder) from a single blood sample for early cancer detection.
• AVRT (Added Value Risk Test) Cancer prevention program that assesses inflammatory and metabolic pathways to identify early risk factors that may lead to cancer, providing actionable information and lifestyle modification guidance to reduce cancer risk.
• ColonSentry First liquid biopsy blood test for colorectal cancer detection, using RT-PCR to measure RNA transcript expression of seven biomarker genes (ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1, IL2RB) in whole blood samples.
• BreastSentry Blood-based biomarker test for breast cancer risk assessment using plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.
• Prostate Health Index Blood test improving prediction of prostate cancer using [-2]proPSA combined with total and free PSA measurements for enhanced prostate cancer detection in the 2.0 to 10.0 ng/ml PSA range.
• COC Protocol (Care Oncology Clinic) Adjunctive cancer therapy program supervised by oncologists, applying metabolic oncology expertise to support cancer patients alongside standard treatments, delivered through the Care Oncology Clinic physician network.

Quantifiable outcome

• 58% reduction in breast cancer costs through early intervention ($3.4M cost avoidance per 1,000 employees)
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Teen Cancer AmericaminorStrategic or Co-development Partner · 24 November 2021Partnership featured in Virginia Business to support adolescent and young adult cancer patients with early detection services.
• Clinics Operations LimitedcoreStrategic or Co-development Partner · 17 August 2021Acquired specialist clinical services provider from Health Clinics Limited to expand StageZero's capabilities in early detection and prevention of cancer and other diseases. Acquisition adds approximately $4 million in annual revenue and expands telehealth services in Europe and North America.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GRAIL: Directly comparable multi-cancer early-detection blood test developer (Galleri) — competes head-to-head with StageZero's ARISTOTLE in pan-cancer screening, explicitly referenced in STAT News coverage of StageZero.
• Natera: Develops blood-based tests for oncology (Signatera MRD) and reproductive health — directly comparable blood-based diagnostics provider using cfDNA/molecular approaches similar to StageZero's Sentinel Principle.
• Guardant Health: Liquid biopsy oncology diagnostics company with blood-based tests for CRC screening (Shield) and comprehensive genomic profiling — closely mirrors StageZero's blood-based oncology detection model.
• Exact Sciences: Makes Cologuard (stool-DNA CRC screening) and acquired Thrive Earlier Detection — directly competes with StageZero's ColonSentry liquid biopsy and with multi-cancer screening ambitions.

Emerging players

• VolitionRx: Blood-based diagnostic company using Nu.Q nucleosome biomarker technology for cancer detection — competing niche blood-based oncology diagnostics player with similar product architecture to StageZero's panel-based approach.
• Freenome: Earlier-stage multiomics blood-test company pursuing early CRC detection and multi-cancer screening — overlapping with ARISTOTLE and ColonSentry use cases but focused on cell-free DNA methylation vs StageZero's mRNA approach.
• Thrive Earlier Detection: Developer of CancerSEEK multi-cancer blood test, acquired by Exact Sciences — closest emerging direct peer to ARISTOTLE in pan-cancer liquid biopsy, now inside Exact Sciences' commercial footprint.
• Biodesix: Blood-based diagnostics company with lung nodule and oncology proteomic tests — adjacent small-cap blood diagnostics peer pursuing similar employer and clinician channel strategies.

Broad incumbents

• NeoGenomics: Large oncology-focused clinical laboratory offering both LDT and commercial oncology testing services — broader incumbent in the same oncology diagnostics category that touches StageZero's clinical lab model.

Others

• Personal Genome Diagnostics (Labcorp): Liquid biopsy/cancer genomics innovator now part of Labcorp — overlaps with StageZero's molecular oncology offering but embedded in a much larger clinical lab distribution platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/stagezerols
• YouTubeyoutube.com/@StageZeroLifeSciences/featured
• Facebookfacebook.com/StageZeroLifeSciences
• LinkedInlinkedin.com/company/stagezero-lifesciences/?viewAsMember=true

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds12 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StageZero Life Sciences